GCP
ORIC icon

GSA Capital Partners’s Oric Pharmaceuticals ORIC Stock Holding History

GSA Capital Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Sell
12,770
-57,864
-82% -$657K 0.01% 1500
2025
Q4 		$578K Buy
70,634
+38,706
+121% +$446K 0.05% 713
2025
Q3 		$383K Buy
+31,928
New +$336K 0.03% 1041
2025
Q2 		– Sell
-15,844
Closed -$88K – 2041
2025
Q1 		$88K Buy
+15,844
New +$139K 0.01% 1516
2024
Q1 		– Sell
-24,515
Closed -$226K – 1878
2023
Q4 		$226K Sell
24,515
-9,503
-28% -$68.7K 0.02% 1258
2023
Q3 		$206K Sell
34,018
-85,472
-72% -$700K 0.02% 1276
2023
Q2 		$927K Sell
119,490
-22,915
-16% -$130K 0.09% 354
2023
Q1 		$812K Sell
142,405
-95,954
-40% -$501K 0.08% 431
2022
Q4 		$1.4M Buy
238,359
+12,759
+6% +$43.1K 0.17% 80
2022
Q3 		$722K Buy
225,600
+174,965
+346% +$700K 0.1% 326
2022
Q2 		$227K Buy
50,635
+8,128
+19% +$32.4K 0.03% 1008
2022
Q1 		$227K Buy
42,507
+18,553
+77% +$167K 0.03% 1096
2021
Q4 		$352K Buy
+23,954
New +$374K 0.04% 828

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GSA Capital Partners's ORIC Position: Q1 2026 in Review

GSA Capital Partners reduced its Oric Pharmaceuticals (ORIC) stake by 82% in Q1 2026, selling an estimated $657K and leaving 12,770 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #1500.

GSA Capital Partners first reported a position in ORIC in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.4M in Q4 2022. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • GSA Capital Partners held 12,770 shares of Oric Pharmaceuticals worth $162K as of Q1 2026.
  • GSA Capital Partners sold 57,864 Oric Pharmaceuticals shares in Q1 2026, an estimated $657K.
  • Oric Pharmaceuticals made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1500 holding.
  • GSA Capital Partners first reported a position in Oric Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • GSA Capital Partners's Oric Pharmaceuticals position peaked at $1.4M in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.